42 reports of this reaction
3.2% of all SELEGILINE HYDROCHLORIDE reports
#3 most reported adverse reaction
DYSKINESIA is the #3 most commonly reported adverse reaction for SELEGILINE HYDROCHLORIDE, manufactured by Bausch Health US, LLC. There are 42 FDA adverse event reports linking SELEGILINE HYDROCHLORIDE to DYSKINESIA. This represents approximately 3.2% of all 1,332 adverse event reports for this drug.
Patients taking SELEGILINE HYDROCHLORIDE who experience dyskinesia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSKINESIA is moderately reported among SELEGILINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to dyskinesia, the following adverse reactions have been reported for SELEGILINE HYDROCHLORIDE:
The following drugs have also been linked to dyskinesia in FDA adverse event reports:
DYSKINESIA has been reported as an adverse event in 42 FDA reports for SELEGILINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSKINESIA accounts for approximately 3.2% of all adverse event reports for SELEGILINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience dyskinesia while taking SELEGILINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.